

Integrated Medicine Optimisation Committee Drug Decision Making Recommendation Summary

The Integrated Medicines Optimisation Committee (IMOC) now includes the drug decision making responsibilities for the Dorset system.
The Dorset Medicines Advisory Group has been absorbed into the IMOC.

Summary of recommendations made by the group August 2025. Formulary entries and associated documents can be accessed at www.dorsetformulary.nhs.uk.

PRODUCT	DECISION		COMMENTS
1. Products re-categorised	Previous position	Recommended position	
<ul style="list-style-type: none"> GlucoRx Nexus blood glucose test strips Glucoszen Lancets 	Green	Non-formulary	NHS England » Commissioning recommendations following the national assessment of blood glucose and ketone meters, testing strips and lancets
<ul style="list-style-type: none"> Freestyle Libre 2 sensors 	Amber, initiated	Non-formulary	Discontinued 31 st August 2025
2. New requests			
<ul style="list-style-type: none"> GlucoRx Q test strips GlucoRx Smart glucose test strips GlucoRx Vivid test strips Neon GK+ test strips Palmdoc Test strips Klinion soft fine lancet 	Green		NHS England » Commissioning recommendations following the national assessment of blood glucose and ketone meters, testing strips and lancets

PRODUCT	DECISION	COMMENTS
<ul style="list-style-type: none"> Kinetik Wellbeing lancets 		
<ul style="list-style-type: none"> ALLY lancets GlucoJect Lancets Extra Apollo BV Safety Lancets GlucoRx Lite Safety Lancets Palmdoc Lancets Apollo Pressure-activated safety lancets MicroDot HiFlow Safety Lancet MicroDot Lite Safety Lancet MicroDot Professional Safety Lancet Apollo Tri-Plus Safety Lancets Mylife Safety Lancets/ Comfort Greenfine lancets Apollo Twist lancets 	Green	NHS England » Commissioning recommendations following the national assessment of blood glucose and ketone meters, testing strips and lancets
Sildenafil orodispersible films	Non formulary	
Fresubin plant based	Red	As an alternative to Fortisip plant-based feed
Octreotide Injection	Red	For surgical use at UHD
Levothyroxine IV	Red	Added for UHD only
Nefopam	Red	For UHD new indication added – for chest wall trauma

Denosumab 120mg	Red	For UHD only, (Restricted Item Maximum of 5 patients per financial year) for the prevention of skeletal-related events in patients with bone metastases from multiple myeloma and reduced renal function (Creatinine Clearance <30mL/min)
Nemolizumab	Red	In accordance with NICE TA1077
Sparsentan	Red	In accordance with NICE TA1074
Spesolimab	Red	In accordance with NICE TA1070
Betula verrucosa	Red	In accordance with NICE TA1087

3. Products considered by NICE
<ul style="list-style-type: none"> • Overview Mirikizumab for previously treated moderately to severely active Crohn's disease Guidance NICE • Overview Dapagliflozin for treating chronic kidney disease Guidance NICE • Overview Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over Guidance NICE • Overview Sparsentan for treating primary IgA nephropathy Guidance NICE • Overview Spesolimab for treating generalised pustular psoriasis flares Guidance NICE • Overview Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen Guidance NICE
4. Miscellaneous recommendations by IMOC
link to CBT for Menopausal Symptoms to the Formulary 02-WHC-FACTSHEET-CBT-WOMEN-FEB-2023-A.pdf
5. Further Assessment / Evidence Required
6. New documents – For Noting
Denosumab 60mg in osteoporosis - prescribing support document
Pharmacological Management of Sialorrhoea in Adult Patients with Neurological Disorders

7. Documents Reviewed
Amiodarone patient information leaflet updated
Anti-microbial wound care product guidance updated
Definitions of Traffic Light Categorisation guidance updated
PGD update: Cytisine
PGD update: Ulipristal Acetate
PGD update: Varenicline
PGD update: Levonorgestrel

Classification of products:

‘RED’ drugs for hospital use only

‘Amber recommended’ is for drugs which primary care would appreciate advice regarding diagnosis or management of a patient from a specialist before initiating a drug within primary care.

‘Amber initiated’ is for drugs which due to diagnosis, monitoring or a stabilisation period need to be started by a specialist before a transfer of prescribing responsibility can be requested to transfer to primary care.

‘Amber with a shared care protocol’ is for drugs where there is an ongoing need for specialist involvement during the lifetime of the use of the drug and monitoring is required 6 monthly or more frequently. (Note a specialist may be working in the community, not solely secondary or tertiary care).

‘GREEN’ drugs suitable for prescribing in primary and secondary care

‘GP-GREY’ drugs suitable for use in any setting but should be purchased OTC in primary care where exceptions do not apply

‘Not Recommended’ – drugs not recommended for use in Dorset